PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Schlepckow, K.* ; Monroe, K.M.* ; Kleinberger, G.* ; Cantuti-Castelvetri, L.* ; Parhizkar, S.* ; Xia, D.* ; Willem, M.* ; Werner, G.* ; Pettkus, N.* ; Brunner, B.* ; Sülzen, A.* ; Nuscher, B.* ; Hampel, H.* ; Xiang, X.* ; Feederle, R. ; Tahirovic, S.* ; Park, J.I.* ; Prorok, R.* ; Mahon, C.* ; Liang, C.C.* ; Shi, J.* ; Kim, D.J.* ; Sabelström, H.* ; Huang, F.* ; Di Paolo, G.* ; Simons, M.* ; Lewcock, J.W.* ; Haass, C.*

Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region.

EMBO Mol. Med. 12:e11227 (2020)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Triggering receptor expressed on myeloid cells 2 (TREM2) is essential for the transition of homeostatic microglia to a disease-associated microglial state. To enhance TREM2 activity, we sought to selectively increase the full-length protein on the cell surface via reducing its proteolytic shedding by A Disintegrin And Metalloproteinase (i.e., alpha-secretase) 10/17. We screened a panel of monoclonal antibodies against TREM2, with the aim to selectively compete for alpha-secretase-mediated shedding. Monoclonal antibody 4D9, which has a stalk region epitope close to the cleavage site, demonstrated dual mechanisms of action by stabilizing TREM2 on the cell surface and reducing its shedding, and concomitantly activating phospho-SYK signaling. 4D9 stimulated survival of macrophages and increased microglial uptake of myelin debris and amyloid beta-peptide in vitro. In vivo target engagement was demonstrated in cerebrospinal fluid, where nearly all soluble TREM2 was 4D9-bound. Moreover, in a mouse model for Alzheimer's disease-related pathology, 4D9 reduced amyloidogenesis, enhanced microglial TREM2 expression, and reduced a homeostatic marker, suggesting a protective function by driving microglia toward a disease-associated state.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
8.821
2.057
51
91
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Alzheimer's Disease ; Amyloid Beta-peptide ; Microglia ; Therapeutic Antibody ; Trem2; Amyloid Precursor Protein; Alzheimers-disease; Brain; Generation; Ectodomain; Presenilin; Responses; Cleavage; Survival; Mouse
Sprache englisch
Veröffentlichungsjahr 2020
HGF-Berichtsjahr 2020
ISSN (print) / ISBN 1757-4676
e-ISSN 1757-4684
Zeitschrift EMBO Molecular Medicine
Quellenangaben Band: 12, Heft: 4, Seiten: , Artikelnummer: e11227 Supplement: ,
Verlag Wiley
Verlagsort Chichester
Begutachtungsstatus Peer reviewed
Institut(e) CF Monoclonal Antibodies (CF-MAB)
POF Topic(s) 30201 - Metabolic Health
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-502210-001
DOI 10.15252/emmm.201911227
WOS ID WOS:000526640800001
Scopus ID 85081240935
PubMed ID 32154671
Erfassungsdatum 2020-05-04
[➜Korrektur melden]